Fibroblast Growth Factor 23: Mineral Metabolism and beyond

Contributions to Nephrology

Volumn 190, Issue , 2017, Pages 83-95

  Grabner, Alexander ^a   Mazzaferro, Sandro ^b   Cianciolo, Giuseppe ^c   Krick, Stefanie ^d   Capelli, Irene ^c   Rotondi, Silverio ^b   Ronco, Claudio ^e,f   La Manna, Gaetano ^c   Faul, Christian ^g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d University of Alabama at Birmingham   (United States)

^e Dialysis and Transplantation ^*  (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MINERAL;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; HUMAN; METABOLISM; PHYSIOLOGY;

BIOMARKERS; CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; HUMANS; MINERALS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85020295627     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000468952     Document Type: Article

References (37)

1. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
2. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568.
3. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
4. Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, et al: FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 2014; 33: 229-246.
5. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al: Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2016; 89: 135-146.
6. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
7. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015; 22: 1020-1032.
8. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al: Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 2016; 90: 985-996.
9. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstadt HJ, Meersch M, et al: FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126: 962-974.
10. Vervloet MG, van Zuilen AD, Heijboer AC, ter Wee PM, Bots ML, Blankestijn PJ, et al: Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol 2012; 13: 20.
11. Ravikumar P, Ye J, Zhang J, Pinch SN, Hu MC, Kuro-o M, et al: α-Klotho protects against oxidative damage in pulmonary epithelia. Am J Physiol Lung Cell Mol Physiol 2014; 307:L566-L575.
12. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
13. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
14. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, et al: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
15. Leifheit-Nestler M, Gro.e Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, et al: Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31: 1088-1099.
16. Scialla JJ, Wolf M: Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014; 10: 268-278.
17. Mazzaferro S, Pasquali M, Pirro G, Rotondi S, Tartaglione L: The bone and the kidney. Arch Biochem Biophys 2010; 503: 95-102.
18. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al: Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7: 1155-1162.
19. Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, et al: Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 2017; 91: 711-719.
20. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK: Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol 2016; 27: 227-237.
21. Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, et al: Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol 2016; 1: 548-556.
22. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 2007; 18: 2600-2608.
23. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, et al: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168.
24. Tsai MH, Leu JG, Fang YW, Liou HH: High fibroblast growth factor 23 levels associated with low hemoglobin levels in patients with chronic kidney disease stages 3 and 4. Medicine (Baltimore) 2016; 95:e3049.
25. Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al: Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 2017; 317: 156-164.
26. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al: Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24: 842-852.
27. Cianciolo G, Galassi A, Capelli I, Angelini ML, La Manna G, Cozzolino M: Vitamin D in kidney transplant recipients: mechanisms and therapy. Am J Nephrol 2016; 43: 397-407.
28. Cianciolo G, Cozzolino M: FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde. Clin Kidney J 2016; 9: 665-668.
29. Evenepoel P, Meijers BK, de Jonge H, Naesens M, Bammens B, Claes K, et al: Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829-1836.
30. Sanchez Fructuoso AI, Maestro ML, Perez-Flores I, Valero R, Rafael S, Veganzones S, et al: Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Nephrol Dial Transplant 2012; 27: 4227-4235.
31. Scolari MP, Cappuccilli ML, Lanci N, La Manna G, Comai G, Persici E, et al: Predictive factors in chronic allograft nephropathy. Transplant Proc 2005; 37: 2482-2484.
32. Riella LV, Djamali A, Pascual J: Chronic allograft injury: mechanisms and potential treatment targets. Transplant Rev (Orlando) 2016; 31: 1-9.
33. Olauson H, Lindberg K, Amin R, Sato T, Jia T, Goetz R, et al: Parathyroid-specific deletion of Klotho unravels a novel calcineurindependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 2013; 9:e1003975.
34. Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, et al: A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 2016; 100: 184-193.
35. Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH: Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 1968-1978.
36. Cianciolo G, La Manna G, Cappuccilli ML, Lanci N, Della Bella E, Cuna V, et al: VDR expression on circulating endothelial progenitor cells in dialysis patients is modulated by 25(OH)D serum levels and calcitriol therapy. Blood Purif 2011; 32: 161-173.
37. La Manna G, Cappuccilli ML, Cianciolo G, Conte D, Comai G, Carretta E, et al: Cardiovascular disease in kidney transplant recipients: the prognostic value of inflammatory cytokine genotypes. Transplantation 2010; 89: 1001-1008.